Isocitrate Dehydrogenase (IDH)

异柠檬酸脱氢酶 (IDH) 是柠檬酸循环中的关键酶之一,可催化异柠檬酸氧化脱羧为 α-酮戊二酸 (α-KG),生成二氧化碳和 NADPH/NADH。IDH 属于一个古老的大家族,在能量代谢、氨基酸生物合成和维生素生产中发挥着核心作用。

IDH 蛋白家族由三种自调节酶 (IDH1、IDH2 和 IDH3) 组成。IDH1 和 IDH2 都是烟酰胺腺嘌呤二核苷酸磷酸 (NADP) 依赖性酶,可催化异柠檬酸氧化脱羧为 α-酮戊二酸 (α-KG),同时在过氧化物酶体和细胞质 (IDH1) 或线粒体 (IDH2) 中产生 NADPH。IDH3 催化线粒体中的相同反应,但以 NAD 依赖的方式进行。已证实 IDH1 和 IDH2 突变存在于多种恶性肿瘤中。IDH 抑制剂为 IDH1/2 突变型髓系恶性肿瘤带来了希望。

Isocitrate dehydrogenase (IDH), one of the key enzymes in the citric acid cycle, catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG) generating carbon dioxide and NADPH/NADH. IDHs belong to a large ancient family of enzymes that play central roles in energy metabolism, amino acid biosynthesis and vitamin production.

IDH protein family consists of three self-regulating enzymes (IDH1, IDH2, and IDH3). IDH1 and IDH2 are both nicotinamide adenine dinucleotide phosphate (NADP)-dependent enzymes that catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), while producing NADPH either in peroxisomes and the cytosol (IDH1) or in mitochondria (IDH2). IDH3 catalyzes the same reaction in the mitochondria, but in a NAD-dependent fashion. Mutations in IDH1 and IDH2 have been demonstrated in a variety of malignancies. IDH inhibitors have engendered hope in IDH1/2 mutant myeloid malignancies.

Isocitrate Dehydrogenase (IDH)亚型特异性产品:Isocitrate Dehydrogenase (IDH) Isoform Comparison
共 3种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
(R,S)-Ivosidenib
(R,S)-AG-120

(R,S)-Ivosidenib ((R,S)-AG-120) 是活性较低的 Ivosidenib (AG-120) 的 (R,S)-对映体,而 Ivosidenib 可用于 IDH1 突变癌症的研究。

2070009-31-1
Control
98.01%
(R,S)-Ivosidenib
(S,R)-GSK321

(S,R)-GSK321 是 GSK321 (MS-A12599) 的 (S,R)-对映体,而 GSK321 是一种有效的选择性突变型 IDH1 抑制剂,对 R132G、R132C、R132H 和 WT IDH1 的 IC50 值分别为 2.9、3.8、4.6 和 46 nM,选择性比 IDH2 高出 100 倍,可诱导细胞内 2-HG 减少、使髓细胞分化阻滞失效,并在白血病母细胞和更不成熟的干细胞水平诱导粒细胞分化,因此可用于急性髓系白血病 (AML) 及其他癌症的研究。

1816272-18-0
Control
98.62%
(S,R)-GSK321
GSK990

GSK990 是一种无活性的突变型 IDH1 抑制剂,对野生型或突变型 IDH1/IDH2 酶均无显著抑制活性,可作为无活性 IDH1 抑制剂 GSK321 (MS-A12599) 的阴性对照,用于急性髓系白血病的研究。

1816331-64-2
Control
GSK990

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础